Jupiter Neurosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is JUNS moving today?
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for JUNS.
JUNS insider activity
Jupiter Neurosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for JUNS.
JUNS contract awards, year to date.
Public federal awards linked to this ticker.
JUNS lobbying filings, year to date.
Registered lobbying filings matched to Jupiter Neurosciences, Inc. Common Stock.